Search Images Maps Play YouTube Gmail Drive Calendar More »
Settings | Sign in

GlaxoSmithKline

Lloyds Banking Group plc vs GlaxoSmithKline plc: which is the better growth stock?

Motley Fool UK - ‎May 27, 2016‎
But regardless of which stock you may personally prefer, I believe both Lloyds and GlaxoSmithKline provide great value relative to their long-term growth prospects, the firms dealing on prospective P/E ratings of 9.3 times and 16.1 times respectively ...

There has never been a better time to buy GlaxoSmithKline plc, Persimmon plc and Admiral Group plc

Motley Fool UK - ‎May 27, 2016‎
If you are investing in shares, what do you look for? Well, I would say a key component is growth: increasing revenues and increasing earnings.

BRIEF-GlaxoSmithKline appoints Vivienne Cox to board

Reuters - ‎May 27, 2016‎
BRIEF-GlaxoSmithKline appoints Vivienne Cox to board. May 27 Glaxosmithkline Plc. * Board and committee changes. * Dr Vivienne Cox, CBE, has been appointed to board of company as a non-executive director with effect from 1 July 2016 Source text for ...
See realtime coverage

Ionis Hits 3-Year Low As GlaxoSmithKline Drops Big Trial Plans

Investor's Business Daily - ‎May 26, 2016‎
Shares of biotech Ionis Pharmaceuticals (IONS) plummeted to a nearly three-year low Thursday after its partner GlaxoSmithKline (GSK) said it won't pursue a late-stage trial of Ionis' rare-disease drug. The news lifted Alnylam (ALNY), which has a rival ...

How Pennon Group plc (3.91%) could soon yield more than GlaxoSmithKline plc (5.50%) and Rio Tinto plc (7.40%).

Motley Fool UK - ‎May 26, 2016‎
When comparing company dividends, you need to do more than simply look at today's headline yield. In these uncertain times, with a number of big-name FTSE 100 companies slashing their payouts over the last year, you need to see how well that dividend ...
See realtime coverage

GlaxoSmithKline's Strimvelis Gets European Marketing Authorisation to Treat Rare Disease ADA-SCID (NYSE:GSK)

Sonoran Weekly Review - ‎22 hours ago‎
GlaxoSmithKline (NYSE:GSK), Fondazione Telethon and Ospedale San Raffaele announced the European Commission has approved Strimvelis, the first ex-vivo stem cell gene therapy to treat patients with the rare disease called ADA-SCID, or severe ...

GlaxoSmithKline Pharma March quarter net at Rs. 106 cr.

The Hindu - ‎May 25, 2016‎
The company had posted a net profit of Rs. 102.9 crore for the same period in the previous fiscal, GlaxoSmithKline Pharmaceuticals said in a BSE filing.
See realtime coverage

GlaxoSmithKline Pharma March Quarter Net At Rs. 106 Crore

NDTV - ‎May 25, 2016‎
New Delhi: GlaxoSmithKline Pharmaceuticals on Wednesday reported a standalone net profit of Rs. 105.98 crore for the quarter ended March 31, 2016.
See realtime coverage

GlaxoSmithKline lung study shows positive results

MarketWatch - ‎May 24, 2016‎
LONDON--GlaxoSmithKline PLC (GSK.LN) Tuesday said the Salford lung study for chronic obstructive pulmonary disease, in collaboration with Innoviva Inc. INVA, -1.76% has had positive headline results.

Are Aviva plc, GlaxoSmithKline plc and Royal Dutch Shell plc the FTSE 100's best bargains?

AOL Money UK - ‎May 20, 2016‎
GlaxoSmithKline has seen earnings slide during the past four years as exclusivity lapses across key products have dented revenues growth.

Are GlaxoSmithKline plc, Tissue Regenix Group plc and Optibiotix Health plc must-have health stocks?

Motley Fool UK - ‎May 23, 2016‎
Top FTSE 100 pharmaceuticals group GlaxoSmithKline (LSE: GSK) may have endured a challenging few years, but it remains a core stock for a portfolio in my view.

Glaxosmithkline Plc (NYSE:GSK) Shorted Shares Increased By 21.13%

The Post - ‎3 hours ago‎
The stock of Glaxosmithkline Plc (NYSE:GSK) registered an increase of 21.13% in short interest. GSK's total short interest was 4.84 million shares in May as published by FINRA.

Time to buy GlaxoSmithKline plc and Carillion plc?

Motley Fool UK - ‎May 20, 2016‎
Today I'll be taking a closer look at construction services company Carillion (LSE: CLLN), and pharmaceuticals giant GlaxoSmithKline (LSE: GSK). Is it the right time to invest in these Great British businesses?

You could beat the market with GlaxoSmithKline plc and Shire plc

Motley Fool UK - ‎May 19, 2016‎
GlaxoSmithKline (LSE: GSK) and Shire (LSE: SHP) are two such companies. Shire is a world-leading producer of rare disease treatments, and the company is unlikely to be displaced from this position anytime soon.
See realtime coverage

Analyst Coverage: GlaxoSmithKline PLC (NYSE:GSK)

Risers & Fallers - ‎May 26, 2016‎
Recently stock market analysts have updated their consensus ratings on shares of GlaxoSmithKline PLC (NYSE:GSK). The latest broker reports which are currently outstanding on Thursday 26th of May state 0 analysts have a rating of “strong buy”, 0 ...

Welch & Forbes LLC Increased Glaxosmithkline Plc (NYSE:GSK) by $6.90 Million as Shares Rose

CCH Daily News - ‎May 27, 2016‎
Welch & Forbes Llc increased its stake in Glaxosmithkline Plc (NYSE:GSK) by 34.66% based on its latest 2016Q1 regulatory filing with the SEC.

BRIEF-Glaxosmithkline and Innoviva report positive headline results in Salford Lung study

Reuters - ‎May 24, 2016‎
May 24 Glaxosmithkline Plc : * Co and Innoviva announced positive headline results from innovative salford lung study in chronic obstructive pulmonary disease.

Is BTG plc a better buy than GlaxoSmithKline plc?

Motley Fool UK - ‎May 17, 2016‎
British investing great Neil Woodford has said several times that the pharmaceutical industry is one of Britain's great strengths, and is worthy of investing in.

Why GlaxoSmithKline plc, Allergy Therapeutics plc and Consort Medical plc are a dying breed

Motley Fool UK - ‎May 18, 2016‎
One notable business within the healthcare sector is GlaxoSmithKline (LSE: GSK). It offers a large amount of diversity through having three segments to its business, with pharmaceuticals, vaccines and consumer goods combining to create a relatively low ...
 -